{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF00531",
      "entity_text" : "death",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:11949646",
      "entity_text" : "empagliflozin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The study clearly demonstrated that empagliflozin reduced the primary MACE end point (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 14%.",
  "reading_complete" : "2020-07-28T16:25:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T16:24:07Z",
  "trigger" : "reduced",
  "evidence" : [ "empagliflozin reduced the primary MACE end point (cardiovascular death" ],
  "pmc_id" : "5013718",
  "score" : 0
}